CARTIVA GRIP Trial
A prospective, multicentre clinical trial to assess safety and efficacy of a synthetic cartilage implant for treatment of Eaton-Littler stage II/III first CMC joint osteoarthritis

Trial Investigators:
- Chris Bainbridge
- Sangey Miranda
- Grey Giddins
- Jonathan Lee
- Andrew Trehorn
- Phil Suave
- David Lawrie
- Charles Day
- Erin Brown
- Paul Binhammer

50 Patient Feasibility Study (GRIP)
- 9 Sites – 5 UK and 4 Canada
- 50 subjects enrolled & treated
- Follow-up at 2-weeks, 6-weeks, 3-months, 6-months, 1-year, and 2-year
- Mean follow-up 361 days
  - Mo 3 (n=50), Mo 6 (n=49), Mo 12 (n=46)
- Stage II/Ill Eaton Littler
- Average age 61(SD 9.8)
- Female:Male 58:42%

Preliminary Results – Strength Improvement
12 month data by type of operation

GRIP Interim Results - Safety
- Few device related events
  - 4 Pain (1 resolved & 3 ongoing)
  - 1 Finger numbness (ongoing)
  - 1 Osteolysis (resolved)
- Subsequent Secondary Surgical Interventions
  - 4 (8%) conversions to LRTI
  - 2 (4%) supplemental fixations
  - All patients that required a removal were successfully revised to trapeziectomy or LRTI

Pivotal FDA Study for Cartiva CMC
- IDE Approved by FDA in August 2017
  - 74 Cartiva subjects @ 12 sites
  - Evaluating pain, function, strength and safety
  - Results will be compared to LRTI comparator (historical control)
- 1st UK subject enrolled on 22/12/17
- 1st US subject enrolled on 02/2/17
- Data will support PMA Supplement

Company Highlights
- 1st new orthopedic articular surface material approved by FDA since 2001
  - High water content
  - Elastic and compressible
  - Low friction
- Level 1 clinical data (1st MTP)
- 15 years of clinical experience
- 7+ years experience in the foot

Biocompatibility
- Fatigue Testing
- Chemical Characterization
- Biomechanics
- Material Characterization
- Particulate Implant Study

Summary of Patient Outcomes
Clinically Meaningful Improvement
- VAS Pain: 50% decrease
- Quick-DASH: 15 point increase
- MHDQ: 10 point increase

GRIP Strength
- Key Pinch
- Tip Pinch

Contact:
- info@bio-vation.co.uk
- Mobile: +44 (0) 7740097554
- Tel: +44 (0) 114 3992990
- Fax: +44 (0) 114 2679006